← Back to Search

Robotic Interventions for Spasticity Treatment

N/A
Waitlist Available
Led By Jose L Pons, PhD
Research Sponsored by Shirley Ryan AbilityLab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, midpoint of intervention (after 2 weeks), and endpoint (after 4 weeks), 1 month after completing all training sessions, and 3 months after completing all training sessions.
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the effects of three different types of stroke rehabilitation therapies.

Eligible Conditions
  • Muscle stiffness
  • Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, midpoint of intervention (after 2 weeks), and endpoint (after 4 weeks), 1 month after completing all training sessions, and 3 months after completing all training sessions.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, midpoint of intervention (after 2 weeks), and endpoint (after 4 weeks), 1 month after completing all training sessions, and 3 months after completing all training sessions. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in 10-meter walking test
Change in 6-minute walking test
Change in Functional Gait Assessment (FGA)
+8 more
Secondary study objectives
Change in co-activation index of the muscles

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Visual FeedbackExperimental Treatment1 Intervention
The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
Group II: Haptic and Visual FeedbackExperimental Treatment1 Intervention
The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
Group III: Conventional robotic continuous passive movement trainingActive Control1 Intervention
The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Visual Feedback
2016
N/A
~420

Find a Location

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor
208 Previous Clinical Trials
17,865 Total Patients Enrolled
74 Trials studying Stroke
8,707 Patients Enrolled for Stroke
Jose L Pons, PhDPrincipal InvestigatorShirley Ryan AbilityLab
7 Previous Clinical Trials
381 Total Patients Enrolled
5 Trials studying Stroke
336 Patients Enrolled for Stroke

Media Library

Conventional robotic continuous passive movement training Clinical Trial Eligibility Overview. Trial Name: NCT05006248 — N/A
Stroke Clinical Trial 2023: Conventional robotic continuous passive movement training Highlights & Side Effects. Trial Name: NCT05006248 — N/A
Conventional robotic continuous passive movement training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05006248 — N/A
Stroke Research Study Groups: Conventional robotic continuous passive movement training, Visual Feedback, Haptic and Visual Feedback
Stroke Patient Testimony for trial: Trial Name: NCT05006248 — N/A
~16 spots leftby Jan 2026